Epstein–Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma

References

• Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:161–168.
   PubMedGoogle Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337–2344.
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175–1176.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008;13:577–585.
   PubMed Web of Science ®Google Scholar
• Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol 2003;7:336–361.
   PubMedGoogle Scholar
• Hengge UR, Ruzicka T, Tyring SK, et al Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002;2:344–352.
   PubMed Web of Science ®Google Scholar
• Vilchez RA, Madden CR, Kozinetz CA, et al Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002;359:817–823.
   PubMed Web of Science ®Google Scholar
• Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 2008;31:2391–2397.
   PubMed Web of Science ®Google Scholar
• Milani C, Pascual S, Mitri J, et al Non-Hodgkin lymphoma and smoking: a meta-analysis of case–control studies. Blood (Suppl) 2008;112:5292(Abstract).
   Google Scholar
• Cerhan JR, Engels EA, Cozen W, et al Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case–control study. Int J Cancer 2008;123:888–894.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, 4th ed. 2008; IARC.Lyon:
   Google Scholar
• Armitage JO. The changing classification of non-Hodgkin's lymphomas. CA Cancer J Clin 1997;47:323–325.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, et al Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18:3707–3721.
   PubMed Web of Science ®Google Scholar
• Kanavaros P, Briere J, Emile JF, et al Epstein–Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Leukemia 1996;10(Suppl 2): s84–s87.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002;17:539–554.
   PubMed Web of Science ®Google Scholar
• Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008;83:804–809.
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Peiper SC. Detection of Epstein–Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases by the polymerase chain reaction technique. Mod Pathol 1990;3:435–441.
   PubMed Web of Science ®Google Scholar
• Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al Expression of Epstein–Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320–322.
   PubMed Web of Science ®Google Scholar
• Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002;10:7–14.
   PubMedGoogle Scholar
• Keegan TH, Glaser SL, Clarke CA, et al Epstein–Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005;23:7604–7613.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Emile JF, Mounier N, et al Prognostic significance of Epstein–Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006;108:4163–4169.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al The impact of Epstein–Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972–978.
   PubMed Web of Science ®Google Scholar
• Kuze T, Nakamura N, Hashimoto Y, et al The characteristics of Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res 2000;91:1233–1240.
   PubMedGoogle Scholar
• Yoshino T, Nakamura S, Matsuno Y, et al Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci 2006;97:163–166.
   PubMed Web of Science ®Google Scholar
• Oyama T, Yamamoto K, Asano N, et al Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007;13:5124–5132.
   PubMed Web of Science ®Google Scholar
• Heller KN, Steinherz PG, Portlock CS, et al EBV-positive lymphoma patients have a selective deficiency in EBV immunity. ASCO Meet Abstr 2007;25(18 Suppl): 21032.
   Google Scholar
• Thompson MP, Kurzrock R. Epstein–Barr virus and cancer. Clin Cancer Res 2004;10:803–821.
   PubMed Web of Science ®Google Scholar
• Huen DS, Henderson SA, Croom-Carter D, et al The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549–560.
   PubMed Web of Science ®Google Scholar
• Roberts ML, Cooper NR. Activation of a ras-MAPK-dependent pathway by Epstein–Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998;240:93–99.
   PubMed Web of Science ®Google Scholar
• Shair KH, Bendt KM, Edwards RH, et al EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog 2007;3:e166.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T, et al A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood 2007;109:2571–2578.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, et al Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110:1123–1131.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC, et al Cytotoxic T lymphocyte therapy for Epstein–Barr virus + Hodgkin's disease. J Exp Med 2004;200:1623–1633.
   PubMed Web of Science ®Google Scholar